Pancreatic ductal adenocarcinoma (PDAC), commonly referred to as pancreatic cancer,
ranks among the leading causes of cancer-related deaths in the Western world due to …

Cancer is a community health hazard which progress at a fatal rate in various countries
across the globe. An agent used for chemotherapy should exhibit ideal properties to be an …

Integrins are a family of heterodimeric cell surface receptors that are expressed in most cells,
where they mediate cell-cell and cell-extracellular matrix (ECM) interactions. Integrin αvβ6 is …

Pancreatic ductal adenocarcinoma is the third-leading cause of all cancer-related deaths in
the US. While 20% of patients have resectable disease at diagnosis, improved control of …

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related
death worldwide, and the mortality of patients with PDAC has not significantly decreased …

Pancreatic ductal adenocarcinoma is one of the most aggressive solid tumours of the
pancreas, characterised by a five-year survival rate less than 8%. Recent reports that …

Pancreatic cancer (PC) incidence rates are rapidly increasing in developed countries, with
half the patients being metastatic at diagnosis. For decades, fluorouracil, then gemcitabine …

Background Treatment with nab-paclitaxel plus gemcitabine increases survival in patients
with metastatic pancreatic cancer. However, the assessment of treatment efficacy and safety …

Abstract Background Cytosolic 5′-nucleotidase 1A (NT5C1A) dephosphorylates non-cyclic
nucleoside monophosphates to produce nucleosides and inorganic phosphates. Here, we …

As one of the most fatal malignancies, pancreatic ductal adenocarcinoma (PDAC) has
significant resistance to the currently available treatment approaches. Gemcitabine, the …